jRCT2031230161招募中不适用
An Open-Label, Multicenter, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies
IQVIA Services japan G.K.0 个研究点目标入组 7 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 7
- 主要终点
- long-term safety
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Other
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Currently participating in a BeiGene-sponsored eligible parent study.
- •Fulfills treatment criteria specified in the parent study protocol.
- •In the opinion of the investigator, the patient will continue to benefit from, and/or tolerate, any of the parent study treatments.
- •The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study. Details for treatment-specific requirements can be found in the relevant appendices.
- •The terms "treatment interruption" and "treatment break" are not interchangeable.
- •Treatment interruption is an unplanned pause in study treatment (eg, due to adverse event). If the interruption is beyond the period allowed by the parent study, the acceptability of restarting study treatment will depend on an agreement between the investigator and the medical monitor of the LTE study.
- •Treatment break is a planned stop of study therapy for a patient who has been treated for significant period of time and derived treatment benefits. For a patient who is on a treatment break with confirmed CR, PR, or SD after 2 years of tislelizumab-containing treatment, and who has evidence of PD within 1 year of start of treatment break, the investigator can consider restarting the study treatment defined in parent study after discussion with the sponsor, contingent on the continued availability of study medications.
- •Female patients of childbearing potential and female partners of nonsterile males must practice highly effective methods of birth control initiated before the first dose of study treatment, for the duration of the study, and after the last dose of study treatment. See Appendix J for contraception methods. More details on treatment-specific requirements can be found in the relevant appendices.
- •Male patients are eligible if abstinent or vasectomized or if they agree to use contraception for the duration of the study, and after the last dose of study treatment. See Appendix J for contraception methods. Nonsterile males receiving investigational drugs or other genotoxic chemotherapeutic treatment must avoid sperm donation for the duration of the study and after the last dose of study treatment. More details on treatment-specific requirements can be found in the relevant appendices.
- •A signed informed consent form obtained before enrolling in this LTE study and receiving study treatment
排除标准
- •Permanently discontinued from all investigational drugs in the parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent.
- •Have uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy 14 days before the planned first dose of treatment in the LTE study
- •Have a life-threatening illness, medical condition, or organ system dysfunction that in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of investigational drugs or put the study outcomes at undue risk
- •Underwent treatment with any systemic anticancer treatment (other than treatment permitted in the parent study) during the time between the last treatment in the parent study and the first dose of study treatment in the LTE study
- •Pregnant or lactating women
- •Inability to comply with study procedures
- •Concurrent participation in another therapeutic clinical trial
结局指标
主要结局
long-term safety
To evaluate the long-term safety of BeiGene investigational drugs in patients with advanced malignancies
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
BGB-3111-LTE1jRCT2011240032BeiGene, Ltd.5
招募中
1 期
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung CancerOncologyMedDRA version: 21.1Level: PTClassification code: 10029517Term: Non-small cell lung cancer stage I Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029516Term: Non-small cell lung cancer stage 0 Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029518Term: Non-small cell lung cancer stage II Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non-small cell lung cancer stage III Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029515Term: Non-small cell lung cancer recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029520Term: Non-small cell lung cancer stage IIIA Class: 100000004864CTIS2023-506539-14-00Systimmune Inc.144
进行中（未招募）
1 期
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864Advanced MelanomaCTIS2023-507377-17-00Microbiotica Limited40
招募中
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCERCTIS2023-508058-24-01ovImmune S.A.12
进行中（未招募）
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCEROCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCERCTIS2023-508058-24-00ovImmune S.A.12